Recent advances in eosinophilia with FGFR rearrangement

Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, gives an update on the management of eosinophilia with fibroblast growth factor receptor (FGFR) rearrangement. Encouraging results from the FIGHT-203 study (NCT03011372) evaluating pemigatinib are expected to improve the outcomes of this patient population. This interview took place virtually.